Rowan Miller

3.6k total citations · 2 hit papers
77 papers, 1.6k citations indexed

About

Rowan Miller is a scholar working on Oncology, Reproductive Medicine and Molecular Biology. According to data from OpenAlex, Rowan Miller has authored 77 papers receiving a total of 1.6k indexed citations (citations by other indexed papers that have themselves been cited), including 41 papers in Oncology, 41 papers in Reproductive Medicine and 19 papers in Molecular Biology. Recurrent topics in Rowan Miller's work include Ovarian cancer diagnosis and treatment (41 papers), PARP inhibition in cancer therapy (31 papers) and BRCA gene mutations in cancer (10 papers). Rowan Miller is often cited by papers focused on Ovarian cancer diagnosis and treatment (41 papers), PARP inhibition in cancer therapy (31 papers) and BRCA gene mutations in cancer (10 papers). Rowan Miller collaborates with scholars based in United Kingdom, United States and France. Rowan Miller's co-authors include Christopher J. Lord, Jonathan A. Ledermann, Alan Ashworth, David S.P. Tan, Rumana Rafiq, James Campbell, Rachel Brough, Asha Konde, Isabelle Ray‐Coquard and Alexandra Léary and has published in prestigious journals such as Nature Communications, Journal of Clinical Oncology and SHILAP Revista de lepidopterología.

In The Last Decade

Rowan Miller

72 papers receiving 1.6k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

ESMO recommendations on predictive biomarker testing for homologous recombination deficiency and PARP inhibitor benefit in ovarian cancer

2020 261 citations Rowan Miller, Christopher J. Lord et al. Annals of Oncology profile →
Newly diagnosed and relapsed epithelial ovarian cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up

2023 149 citations Domenica Lorusso, Rowan Miller et al. Annals of Oncology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Rowan Miller United Kingdom	16	953	820	524	239	226	77	1.6k
Johanne I. Weberpals Canada	20	619 0.6×	687 0.8×	378 0.7×	289 1.2×	127 0.6×	56	1.3k
Rosalind Glasspool United Kingdom	25	722 0.8×	842 1.0×	753 1.4×	193 0.8×	145 0.6×	86	1.9k
Boris Winterhoff United States	21	462 0.5×	749 0.9×	554 1.1×	418 1.7×	138 0.6×	56	1.5k
Anna Måsbäck Sweden	22	844 0.9×	423 0.5×	397 0.8×	362 1.5×	145 0.6×	48	1.8k
Stuart Spencer United Kingdom	16	1.7k 1.8×	902 1.1×	941 1.8×	238 1.0×	125 0.6×	48	2.2k
Matin Sheriff United Kingdom	16	551 0.6×	364 0.4×	316 0.6×	170 0.7×	96 0.4×	33	1.0k
Yasushi Saga Japan	22	354 0.4×	670 0.8×	273 0.5×	251 1.1×	86 0.4×	66	1.4k
Katherine Karakasis Canada	15	494 0.5×	397 0.5×	322 0.6×	215 0.9×	80 0.4×	44	1.0k
Christian Rudlowski Germany	23	478 0.5×	527 0.6×	178 0.3×	422 1.8×	173 0.8×	61	1.6k
Arto Leminen Finland	28	538 0.6×	415 0.5×	590 1.1×	293 1.2×	264 1.2×	60	1.9k

Countries citing papers authored by Rowan Miller

Since Specialization

Citations

This map shows the geographic impact of Rowan Miller's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Rowan Miller with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Rowan Miller more than expected).

Fields of papers citing papers by Rowan Miller

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Rowan Miller. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Rowan Miller. The network helps show where Rowan Miller may publish in the future.

Co-authorship network of co-authors of Rowan Miller

This figure shows the co-authorship network connecting the top 25 collaborators of Rowan Miller. A scholar is included among the top collaborators of Rowan Miller based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Rowan Miller. Rowan Miller is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Yap, Timothy A., Patricia LoRusso, Rowan Miller, et al.. (2025). The DNA-PK inhibitor AZD7648 alone or combined with pegylated liposomal doxorubicin in patients with advanced cancer: results of a first-in-human Phase I/IIa study. British Journal of Cancer. 133(2). 168–177. 2 indexed citations

El-Shakankery, Karim, Kieran Palmer, Uma Mukherjee, et al.. (2024). Ethnicity and Socioeconomic Disparities in Clinical Trial Participation for Ovarian Cancer: A Retrospective Observational Study in London. Cancers. 16(21). 3590–3590.

Man, Kenneth K. C., Shibani Nicum, Rowan Miller, et al.. (2024). The impact of inter-cycle treatment delays on overall survival in patients with advanced-stage ovarian cancer. The Oncologist. 29(11). e1532–e1539. 2 indexed citations

Kipps, Emma, Kenneth K. C. Man, Rebecca Roylance, et al.. (2024). The impact of inter-cycle treatment delays on 5-year all-cause mortality in early-stage breast cancer: A retrospective cohort study. European Journal of Cancer. 210. 114301–114301. 4 indexed citations

Merry, Eve, Michael Flynn, Jonathan A. Ledermann, et al.. (2024). A multicenter retrospective study to assess feasibility, safety and efficacy of first-line carboplatin-paclitaxel versus carboplatin monotherapy in a frail, elderly epithelial ovarian cancer population☆. International Journal of Gynecological Cancer. 35(9). 101853–101853. 1 indexed citations

Kipps, Emma, Kenneth K. C. Man, Martin Förster, et al.. (2023). 250P The impact of inter-cycle treatment delays on progression-free survival in early stage breast cancer. Annals of Oncology. 34. S283–S283. 3 indexed citations

D’Angelo, Armando, James W. Wood, U. Mukherjee, et al.. (2023). 800P Response to chemotherapy following PARP inhibition in UK ovarian cancer (OC) patients. Annals of Oncology. 34. S535–S535. 1 indexed citations

Miller, Rowan, et al.. (2023). Monitoring clone dynamics and reversibility in clonal haematopoiesis and myelodysplastic neoplasm associated with PARP inhibitor therapy—a role for early monitoring and intervention. Leukemia. 38(1). 215–218. 1 indexed citations

Moore, Kathleen N., Antoine Angelergues, Gottfried E. Konecny, et al.. (2023). Phase III MIRASOL (GOG 3045/ENGOT-ov55) study: Initial report of mirvetuximab soravtansine vs. investigator's choice of chemotherapy in platinum-resistant, advanced high-grade epithelial ovarian, primary peritoneal, or fallopian tube cancers with high folate receptor-alpha expression.. Journal of Clinical Oncology. 41(17_suppl). LBA5507–LBA5507. 37 indexed citations

10.

Miller, Rowan, Florian Laforêts, Panoraia Kotantaki, et al.. (2022). The Tumor Microenvironment of Clear-Cell Ovarian Cancer. Cancer Immunology Research. 10(11). 1326–1339. 21 indexed citations

11.

Miller, Rowan, Andrew R. Clamp, Charlie Gourley, et al.. (2022). 2022-RA-1276-ESGO Pembrolizumab monotherapy for advanced clear cell gynaecological cancer: phase II PEACOCC trial. International Journal of Gynecological Cancer. 32. A316–A316. 2 indexed citations

12.

Tinker, Anna V., Renaud Sabatier, Adriano Gravina, et al.. (2022). 2022-RA-1198-ESGO Post hoc analysis of objective response rate by mismatch repair protein dimer loss/mutation status in patients with mismatch repair deficient endometrial cancer treated with dostarlimab. International Journal of Gynecological Cancer. 32. A414–A414. 5 indexed citations

13.

Tinker, Anna V., Bhavana Pothuri, Renaud Sabatier, et al.. (2022). 548P Progression-free survival (PFS) and overall survival (OS) in advanced/recurrent (AR) mismatch repair deficient/microsatellite instability–high or proficient/stable (dMMR/MSI-H or MMRp/MSS) endometrial cancer (EC) treated with dostarlimab in the GARNET study. Annals of Oncology. 33. S798–S799. 2 indexed citations

14.

MacDonald, Nicola, Michelle Lockley, Rowan Miller, et al.. (2022). Surgical management and outcomes for stage 1 malignant ovarian germ cell tumours: A UK multicentre retrospective cohort study. European Journal of Obstetrics & Gynecology and Reproductive Biology. 271. 138–144. 5 indexed citations

15.

O’Donnell, Elizabeth, Sarah C. Markt, Rowan Miller, et al.. (2017). Smoking and Disease Outcomes in Patients With Malignant Germ Cell Tumors. Clinical Genitourinary Cancer. 16(1). 78–84. 8 indexed citations

16.

Williamson, Chris T., Rowan Miller, Helen N. Pemberton, et al.. (2016). ATR inhibitors as a synthetic lethal therapy for tumours deficient in ARID1A. Nature Communications. 7(1). 13837–13837. 270 indexed citations

17.

Bajrami, Ilirjana, Jessica Frankum, Asha Konde, et al.. (2013). Genome-wide Profiling of Genetic Synthetic Lethality Identifies CDK12 as a Novel Determinant of PARP1/2 Inhibitor Sensitivity. Cancer Research. 74(1). 287–297. 279 indexed citations

18.

Bajrami, Ilirjana, et al.. (2013). Identification of miRNA modulators to PARP inhibitor response. DNA repair. 12(6). 394–402. 58 indexed citations

19.

Miller, Rowan & Susana Banerjee. (2013). The current state of pemetrexed in ovarian cancer. Expert Opinion on Investigational Drugs. 22(9). 1201–1210. 2 indexed citations

20.

Egan, Vincent, et al.. (1999). Sensational interests and general personality traits. Journal of Forensic Psychiatry. 10(3). 567–582. 25 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact